Rachel Haurwitz is the CEO and Co-Founder of BenevolentAI a company at the forefront of leveraging artificial intelligence to accelerate drug discovery and development. She previously led Caribou Biosciences a pioneering CRISPR-based genome editing company focused on innovative treatments for genetic diseases. Under her leadership Caribou has made significant strides in the biotech field earning her accolades such as being named one of Business Insider’s “30 Biotech Leaders Under 40”.
666 3rd Ave, 6th Floor, New York, NY 10017